ArticleTurk patoloji dergisi2021
Tall Cell Carcinoma with Reverse Polarity of Breast: Report of a Case with Unique Morphologic and Molecular Features.
Article in Turk patoloji dergisi, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Tall Cell Carcinoma With Reversed Polarity of the Breast: A Case Report.Journal of breast cancer · 2026Article
- Tall cell carcinoma with reversed polarity: case report of a rare special type of breast cancer and review of the literature.Discover oncology · 2025Article
- Tall cell carcinoma with reverse polarity of the breast in a young patient: A case report.International journal of surgery case reports · 2025Article
- Tall cell carcinoma with reversed polarity of breast cancer: a rare case report and review of the literature.Frontiers in oncology · 2025Article
- Clinicopathological characterization of tall cell carcinoma with reversed polarity of the breast: A case report and review of the litterature.International journal of surgery case reports · 2024Article
- Molecular pathology in breast disease: diagnostic, prognostic, and therapeutic tools.Virchows Archiv : an international journal of pathology · 2024Review
- Case report: Triple-negative breast cancer with low tumour-infiltrating lymphocytes infiltration and good prognosis: a case of Tall Cell Carcinoma with Reversed Polarity and review of the literature.Frontiers in oncology · 2024Article
- Case report: Tall cell carcinoma with reversed polarity of the breast: an additional case and review of the literature.Frontiers in oncology · 2024Article
- Tall Cell Carcinoma with Reversed Polarity: Case Report of a Rare Special Type of Breast Cancer and Review of the Literature.Biomedicines · 2023Article
- Breast carcinomas of low malignant potential.Virchows Archiv : an international journal of pathology · 2022Review
- Tall cell carcinoma with reversed polarity: case report with gene sequencing and literature review.Gland surgery · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast carcinomas are a heterogeneous group of malignancy, having variable clinical outcomes depending on their cellular and molecular properties. Tall cell carcinoma with reverse polarity (TCCRP) is a recently described rare entity, which shares morphological features with tall cell variant of papillary thyroid carcinoma but has a distinct morphological, immunohistochemical, and molecular profile. We describe a case of a 40-year-old female patient, who presented with lump in the breast. The patient underwent lumpectomy and was diagnosed as tall cell carcinoma with reverse polarity. Immunohistochemistry and bi-directional Sanger sequencing for IDH2 mutation were used for diagnosis. Tall cell carcinoma with reverse polarity is a rare and newly described entity with characteristic morphological and molecular findings, which carries an excellent prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.